-0.560 (-7.29%)
Range 7.020 - 7.620   (8.55%)
Open 7.510
Previous Close 7.680
Buy Price 7.100
Buy Volume 30
Sell Price 7.110
Sell Volume 40
Volume 2,153,867
Value -
Measurement Type Value
EPS (USD) -0.972
Trailing EPS (USD) -1.142
NAV (USD) 1.568
Cash In Hand (USD) 0.726
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 4.9
Price / Cash In Hand 10.576
Issued & Paid-up Shares 91,677,500
Treasury Shares -
Market Cap (M) 704.083
Par Value (USD) n.a.
Beta - 75 Days 0.832
R-Squared - 75 Days(%) 1.34
Beta - 500 Days 1.089
R-Squared - 500 Days(%) 0.95
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 28 Jul 2021 04:00.
Data powered by
View All Events


Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. It's SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

Loading Chart...